Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria
- 18 November 2003
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (20) , 2450-2452
- https://doi.org/10.1161/01.cir.0000102969.09658.f2
Abstract
Atrial fibrillation (AF) is well known as one of the cardiogenic causes for thromboembolism. Although decreased flow and hypercoagulable state of the blood in the fibrillating atrium have been emphasized as the underlying mechanisms, endocardial dysfunction in maintaining the local coagulation balance could also contribute to the thrombogenesis in AF. The paroxysmal AF model was created by rapid atrial pacing in anesthetized rats. To test the hypothesis that AF induces local coagulation imbalance by disturbing the atrial endocardial function, the gene expression of intrinsic anticoagulant factors, thrombomodulin (TM) and tissue factor pathway inhibitor (TFPI), were determined by means of ribonuclease protection assay, Western blotting, and immunohistochemistry. Rapid atrial pacing for 8 hours significantly decreased TM and TFPI mRNA levels in the left atrium but not in the ventricle, leading to the downregulation of their immunoreactive proteins. Immunohistochemical analysis revealed that TM and TFPI were expressed predominantly in the endocardial cells of the normal atrium, presumably preventing local blood coagulation, and that rapid atrial pacing induced the loss of TM and TFPI expression in the endocardium, leading to deficiency in anticoagulant barriers between the atria and the blood. Rapid atrial pacing acutely downregulated the gene expression of TM and TFPI in the atrial endocardium, thereby inducing local coagulation imbalance on the internal surface of the atrial cavity. These results would support the validity of supplement of anticoagulant molecules deficient in AF.Keywords
This publication has 12 references indexed in Scilit:
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Preventing stroke in patients with atrial fibrillation: Current treatments and new conceptsAmerican Heart Journal, 2003
- Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial FibrillationCirculation, 2002
- Role of Tissue Factor Pathway Inhibitor in the Regulation of Tissue Factor‐Dependent Blood CoagulationCardiovascular Drug Reviews, 2002
- ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and ElectrophysiologyCirculation, 2001
- A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillationJournal of the American College of Cardiology, 2000
- Prevalence of Residual Left Atrial Thrombi Among Patients With Acute Thromboembolism and Newly Recognized Atrial FibrillationArchives of internal medicine (1960), 1995
- Internalization of the anticoagulant thrombomodulin is constitutive and does not require a signal in the cytoplasmic domainImmunology & Cell Biology, 1994
- Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivoJournal of the American College of Cardiology, 1994